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Background: Chronic insulin resistance, exacerbated in the course of pregnancy, is an important pathophysiologic
mechanism of gestational diabetes mellitus (GDM). We hypothesise that the degree of insulin resistance, assessed at
diagnosis of GDM, is a parameter of its pathophysiologic heterogeneity and/or severity. Thus, it offers potential to
open new avenues for the personalization of therapy in affected women.
Methods: 1254 Polish Caucasian women with GDM were recruited into the study. The following parameters were
assessed in the course of the study: body mass index (BMI), parity, weight gain during pregnancy, glycated
haemoglobin, glucose level during an oral glucose tolerance test (OGTT), insulin, insulin resistance and insulin
secretion. The severity of GDM was assessed based on insulin use and daily insulin dose during gestation. In order
to evaluate insulin secretion and insulin resistance the homeostatic method was used (HOMA-B and HOMA-IR,
respectively). We compared all the metabolic parameters and methods of treatment of GDM in women subdivided
by quartiles of insulin resistance.
Results: The HOMA-IR in the whole population ranged from 0.34 to 20.39. The BMI, fasting insulin, fasting glucose
and insulin dose per day increased along with increasing quartiles (HOMA-IR > 1.29). We observed a decrease of
HOMA-B in the third quartile (1.92-2.89) compared with the first quartile (0.34-1.29). Insulin treatment was associated
with HOMA-IR (<1.29 vs. >2.89), OR: 3.37, fasting glucose (≤6.11 vs. >6.11 mmol/dl), OR: 2.61, age (≤30 vs. >30 y. o.),
OR: 1.54, and BMI (<25 vs. ≥25 kg/m2), OR: 1.45. Maximum insulin dose was associated with HOMA-IR, OR: 2.00, after
adjustment for family history of diabetes, and 2-h OGTT glucose.
Conclusion: Insulin resistance assessed by the HOMA index at diagnosis is associated with the severity and
pathophysiological heterogeneity of GDM. A HOMA-IR >1.29 points to the major role of insulin resistance,
indicating the need for a treatment aimed at improving tissue sensitivity to insulin. A HOMA-IR 1.29-2.89 suggests
reduced insulin secretion, which is an indication for the introduction of insulin therapy. A HOMA-IR >2.89 indicates
insufficient compensation for insulin resistance, which suggests the need for a treatment aimed at improving
susceptibility of tissues to insulin combined with insulin therapy.
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Table 1 Clinical characteristics of the participants
Characteristic Values
N 1254 patients
Age (years) 29.93 ± 5.23
Prepregnancy BMI (kg/m2) 28.48 ± 4.46
Gestational age at the diagnosis of GDM (week) 23.92 ± 4.91
Positive family history of diabetes 445 (35)
Number of pregnancies 2.02 ± 1.28
Diet therapy 935 (75)
Diet + insulin therapy 319 (25)
Values of parameters are presented as mean ± SD or count (percentage).
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Gestational diabetes (GDM), defined as various degrees
of glucose intolerance diagnosed or detected for the first
time during pregnancy, is the most common metabolic
complication of pregnancy. Diagnosis of GDM is associated
with an increased risk of complications for the mother and
child, both during pregnancy and many years postpartum
[1]. This risk can be reduced by appropriate dietary means
and an increase of physical activity, possibly in combination
with administration of insulin or oral drugs. Despite
numerous studies, the pathophysiology of GDM has not
been elucidated. It is known that GDM is a heterogeneous
pathophysiological state, in which the main mechanism is
possibly the dysfunction of pancreatic beta cells, manifesting
itself in the course of increasing insulin resistance during
pregnancy [2].
Therefore, it is of great importance to search for parame-
ters helpful in individualisation, and thus optimising GDM
treatment, as well as in preventing GDM complications.
The medical literature offers no studies describing strategies
for GDM treatment based on pathophysiological criteria.
Moreover, there is no criterion of adding pharmacological
therapy to diet other than glucose level measurement [3].
Insulin resistance is an important pathogenic mechanism,
which precedes GDM occurrence [4-6]. It is probably
chronic in nature [4,5,7] and is associated with an increased
risk to the mother and child [4]. Recent studies indicate a
direct [8] and indirect [9] relationship between the insulin
resistance indices in the first trimester of pregnancy and the
risk of GDM development, as well as risk of macrosomy.
The HOMA-IR index is based on a single measurement
of glucose and insulin in the blood [10]. It is commonly
used as a parameter of the severity of insulin resistance
and it strongly correlates with direct assessment of insulin
resistance using the euglycemic clamp technique [11].
The aim of the current study was to evaluate the rela-
tionship of the degree of insulin resistance, assessed using
the HOMA-IR index at diagnosis of GDM, with selected
clinical, anthropometric, and biochemical parameters, as
well as with pancreatic beta cell function, in order to
consider the potential use of this index for personalized
therapy. In particular, we considered the following aspects:
1* does the degree of insulin resistance assessed by the
HOMA index at diagnosis of GDM differentiate the
studied population pathophysiologically and clinically,
2* is the parameter associated with the treatment method,
and thus can it be used as a severity marker of GDM.
Material and methods
We carried out a prospective study in which we assessed
selected anthropometric, clinical, and pathophysiological
parameters, as well as the method of treatment used for
gestational diabetes mellitus (GDM) in 1254 women
who have already been diagnosed with GDM in theactual pregnancy. 184 women (15%) had a previous
history of GDM. The criteria for inclusion in the study
were an age range between18 to 35 and pregnancy
resulting from spontaneous conception. Exclusion criteria
were chronic diseases, acute infection at diagnosis or in
the course of the pregnancy, and the receiving of drugs
affecting the carbohydrate metabolism. The characteristics
of the studied population are presented in Table 1.
The study was conducted at the Intensive Diabetologic
and Obstetric Care Unit, Nicolaus Copernicus University
Hospital in Bydgoszcz, between 2003 and 2007. The project
was approved by the University Local Research Ethics
Committee and informed consent was obtained from all
the women.
Method of diagnosis and treatment of gestational
diabetes mellitus
All the pregnant women with no previously diagnosed
diabetes were offered screening for gestational diabetes
mellitus (GDM) with a 1 h 50 g oral glucose challenge
test (GCT) between 24 and 28 weeks of pregnancy. If
fasting plasma glucose evaluated at early prenatal visit
was equal or above 5.5 mmol/l (threshold ≥100 mg/dl)
the GCT test was performed by the gynecologist as soon
as possible accordingly to the Polish Diabetes Society
recommendations. A value equal to or above 7.7 mmol/dl
(threshold ≥140 mg/dl) identified women who underwent a
further 2-h 75-g oral glucose tolerance test (OGTT-Oral
Glucose Tolerance Test). Diagnosis of GDM was in
accordance with World Health Organization criteria [12]
modified by the Polish Diabetes Society. GDM was diag-
nosed when the fasting plasma glucose was equal to or
above 5.5 mmol/l (threshold ≥100 mg/dl) in two distinct
tests, or when the plasma glucose was equal to or above
7.7 mmol/l (threshold ≥140 mg/dl) two hours after a 75 g
oral glucose challenge test.
All the women who were diagnosed with GDM were
advised about diet (23–25 kcal/kg pregravid weight for
obese, 30–34 kcal/kg pregravid weight for normal
weight) and physical activity (walking two–three times
daily, half an hour to one hour per day). Self-monitoring
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and 1 h postprandial. Insulin was started for persistent
fasting blood glucose values ≥5.0 mmol/l and/or 1 h post-
prandial blood glucose values ≥6.6 mmol/l after two weeks
of treatment.
Study methods
To investigate the association between the severity of
insulin resistance and the following parameters: age,
positive family history of diabetes in first-degree relatives,
number of previous pregnancies, prepregnancy body mass
index, weight gain during pregnancy at diagnosis of GDM,
time of diagnosis, and GDM treatment, all studied women
were divided into quartiles accordingly to HOMA-IR
values.
In order to evaluate the treatment method, subjects
were divided into two groups: one group treated with
diet and increased physical exercise only, and women
additionally treated with insulin.
We used the following criteria in order to assess the
severity of GDM: introduction of insulin therapy, the
minimum daily dose of insulin necessary to normalise
glucose concentrations in the initial phase of treatment,
and the maximum daily dose of insulin in the course of
pregnancy.
To assess the independent determinants of insulin therapy
in the studied population we used logistic regression
analysis. In this analysis the dependent variable was the
method of therapy as a categorical variable (diet vs. diet
and insulin). The following factors were taken into account
as an independent categorical variables within this
evaluation: age (≤30 vs. >30 years), prepregnancy BMI
(<25 vs. ≥25 kg/m2), fasting glucose at diagnosis of
GDM (≤6.11 vs. >6.11 mmol/l), diabetes mellitus in
first-degree relatives (yes vs. no), HOMA-IR (1st vs. 4th
quartile e.g. HOMA-IR range 0,34-1,29 vs. 2,89-20,39)
and weight gain at diagnosis of GDM (≤ 8 vs. > 8 kg).
The parity, time of GDM diagnosis, HOMA-B index
and glucose concentration in a 2-h OGTT turned out to
be statistically insignificant in correlation testing and
these parameters were not included in the model.
In the next step we assessed the association between
minimum mean daily dose of insulin necessary to
normalize glucose concentration at the beginning of
therapy and HOMA-IR . The relation was assessed using
logistic regression analysis in order to consider the effect
of potential determinants of initial mean daily dose of
insulin and insulin resistance –HOMA-IR index values.
In separate logistic regression models appropriate inter-
action terms were introduced to assess interactions between
dose of insulin as a categorical variable (1th tertile vs. 3th
tertile e.g. 1–6 vs. >16-116 IU/per day) as an dependent
variable: age, pre-pregnancy BMI, gestational age at
diagnosis( ≤22 vs. >22 week), weight gain at diagnosis,family history of diabetes, and glucose at 2-h OGTT
(8,88 vs. > 8,88 mmol/l) as independent variables.
Finally, we assessed the relation of maximal mean daily
dose of insulin in the course of pregnancy and HOMA-IR
index values using separate logistic regression models.
The appropriate interaction terms were introduced to
models interactions between maximal mean daily insulin
dose as dependent categorical variable (1th tertile vs. 3th
tertile, e.g. 1–22 vs. >54-240 IU/per day) and age,
prepregnancy BMI, HOMA-IR index, family history of
diabetes, weight gain at the diagnosis of GDM, fasting
glucose, and glucose at 2-h OGTT.
The following laboratory parameters were assessed in all
the women at diagnosis of GDM: glycated haemoglobin,
fasting insulin concentration, plasma glucose concentra-
tion in the fasting state and 2-h after oral challenge with
75 g glucose according to WHO recommendations.
Venous blood was collected from the elbow vein and
used as research material. Blood samples were collected
from the patients between 7.30 am and 9.30 am after a
12-hour overnight fast. In order to determine the serum
fasting glucose and insulin concentration, blood samples
were collected in 4.5 ml tubes without anticoagulant, and
subsequently centrifuged at 3000 g, 4°C for 20 minutes.
The concentration of glucose was determined by the glucose
oxidase method using an Olympus AU 400 analyser
(reference range: 3.3-5.5 mmol/l). The concentration of
insulin was measured by the immunoenzymatic method
(MEIA) using AxSYM analyser (reference range: 2–25
μU/ml). The A1C in whole blood was measured by the
turbidimetric method (reference values <6%). All the la-
boratory tests were performed at the hospital’s Department
of Analytics.
The severity of insulin resistance (HOMA-IR index)
and pancreatic beta cell function (HOMA-B index) were
assessed on the basis of a single determination of fasting
glucose and insulin concentrations, using mathematical
formulas described by Mathews and colleagues [10].Statistical analysis
All continuous variables are presented as mean values +/−
SD (standard deviation). Categorical traits are presented
as a count (percentage). Quartiles of HOMA-IR were used
to characterize whole studied population with respect to
the degree of insulin resistance degree. Comparisons
between the subgroups were performed by one-way analysis
of variance (ANOVA) with post-hoc analysis to locate the
differences. The p value of less than 0.05 was considered
significant. Categorical variables were compared by means
of the chi square test. The logistic regression method was
used in assessing the relationship between the severity of
insulin resistance and treatment for GDM (diet vs. diet
and insulin).
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relationship between the severity of insulin resistance
and the minimum initial daily dose (low tertile vs. high
tertile) of insulin or the maximum daily dose of insulin
(low tertile vs. high tertile) in the course of treatment.
Statistical analysis was performed using Statistica for
Windows by StatSoft.
Results
The study population of women demonstrated a relatively
young age, slight obesity, and relatively early GDM diag-
nosis. In most women, the diet treatment was sufficient to
achieve normoglycemia. Only a quarter of the respondents
required the insulin therapy inclusion. The characteristics
of the study population are shown in Table 1.
The characteristics of the study subjects subdivided by the
HOMA-IR quartiles are reported in Table 2. The increasing
degree of insulin resistance in quartiles of HOMA-IR is
associated with a progressive increase in body mass index,
level of insulin and fasting glucose, as well as the fre-
quency of positive family history of diabetes. The A1C
values in the 4th quartile were higher compared to the 1st
and 2nd quartile.
The increased HOMA-IR in the 1st quartile was as-
sociated with a decreased HOMA-B in the 3rd quartile
(p = 0.04).
The minimum mean daily dose of insulin, expressed as
international units (IU) per day required to normalise the
glucose concentration, was higher in the 4th quartile of
HOMA-IR compared with the 1st quartile in the initial
phase of treatment, while the maximum mean daily dose
of insulin assessed during gestation was significantly
higher in the 2nd, 3rd and 4th quartiles in comparison
with the 1st quartile.
In the logistic regression analysis, the need for insulin
therapy was most consistently associated with insulin
resistance index-HOMA-IR value (OR 3.37, 95% Cl 2.10,
5.40), and less consistently with fasting glucose (OR 2.61,
95% CL 1.48, 4.50), age (OR 1.54 95% CL 1.12, 2.11), BMI
(OR 1.45 95% CL 1.03, 2.03 ) and weight gain at the diag-
nosis of GDM (OR 0.72 95% CL 0.52, 0.99). There was no
association between insulin therapy and family history of
diabetes. Results of these analysis are reported in Table 3.
Based on logistic regression models, the minimum mean
daily dose needed for the initial normalisation of glucose
levels was associated with the HOMA-IR index (OR 1.4
95% CL 1.0, 2.0) and with a positive family history of dia-
betes (OR 1.9, 95% CL 1.1, 3.3) after adjustment for age
and BMI. Adjustment for glycaemia in a 2-h OGTT, gesta-
tional week as well as weight accretion at diagnosis of
GDM the association between the minimum dose and the
HOMA-IR does not change. The association is no longer
statistically significant after adjustment for fasting gly-
caemia. The results are presented in Table 4.Based on logistic regression models, the maximum
mean daily dose of insulin in the course of treatment was
associated with HOMA-IR(OR 1.9 95% CL 1.2, 3.0) after
adjustment for age, prepregnancy BMI, family history of
diabetes and fasting glucose. Further adjustment for 2-h
OGTT glucose or weight accretion at diagnosis of GDM
does not change this result. Results of this analysis are
presented in Table 5.
Discussion
The first important observation resulting from our study
is that significant differences occur in the studied popula-
tion of women in terms of the severity of insulin resistance
evaluated using the HOMA-IR index at the time of GDM
diagnosis. According to the International Diabetes Feder-
ation criteria, the HOMA-IR cut-off point to differentiate
between low and high insulin resistance is 2.38, and
HOMA-IR values range from 0.34 to 1.29 in the lowest
quartile, whereas in the 4th quartile these values range
from 2.89 to 20.39. Such differences in the HOMA-IR
indicate a significant pathophysiological variation in the
severity of insulin resistance at the diagnosis of GDM in
the studied population.
Consistent with our results, several previous studies
performed on smaller populations have demonstrated
that HOMA-IR index assessed at diagnosis of GDM
ranged from 1.6 to 25 [13-17].
Interestingly 1/4 of the women in our study (the first
quartile), exhibited a low degree of insulin resistance,
while chronic insulin resistance is present in most of the
GDM women [18-20], and it progresses in the course of
pregnancy.
It is also worth of noticing that the highest rate of insulin
resistance (fourth quartile) occurred in 1/4 of our female
patients, while most women with this type of diabetes
exhibit a mild degree of insulin resistance [18,19].
The results of our study clearly indicate a pathophysio-
logical and clinical variation of GDM in respect to
HOMA-IR values. The value of HOMA-IR index higher
than >1.29 is associated with a higher value of the pre-
pregnancy body mass index, fasting glucose level, insulin
level, and severity of GDM. Values of HOMA-IR in the
range of 1.92-2.89 are specifically associated with reduced
insulin secretion, while values of >2.89 are additionally
associated with a higher HbA1c level and an unchanged
beta cell function, suggesting insufficient compensation
for metabolic demands. It should be emphasised that
there were no statistically significant differences between
the HOMA-IR quartiles in terms of age, parity and time
of diagnosis of GDM.
Our results are consistent with the general opinion
that chronic insulin resistance lies at the core of the
development of the most common form of beta cell
dysfunction present in GDM [21]. The function of the
Table 2 Characteristics of women with gestational diabetes divided by quartiles of HOMA-IR
Insulin resistance- HOMA IR index quartiles
(N, mean, range for each quartile)
Variables N = 308 N = 319 N = 316 N = 311 p-Values
0.97 1.59 2.37 4.90
0.34-1.29 1.29-1.92 1.92-2.89 2.89-20.39
Age (years) M 29.77 29.83 30.17 30.07 0.7378
SD 5.36 4.88 5.28 5.05
Family history of diabetes N 49 66 74 103 <0.0001
% 17.01 22.68 24.92 36.27
Parity M 1.98 2.00 1.34 2.01 0.9886
SD 1.16 1.36 0.07 1.34
Gestational age at diagnosis (week) M 28.28 28.48 28.78 28.04 0.1752
SD 4.30 4.49 3.51 4.68
BMI (kg/m2) M 21.61 22.43 24.75 27.39 <0.00011vs3




Weight gain during gestation (kg) M 7.75 8.42 9.12 8.67 0.00581vs3
SD 4.42 4.64 5.10 6.03
Insulin (pmol/l) M 33.3 52.2 73.5 134.6 <0.00011vs2





HbA1c (%) M 5.39 5.41 5.53 5.66 <0.0001
1vs4
SD 0.45 0.45 0.45 0.51 <0.00012vs4
HOMA B index M 490.47 391.52 361.85 468.08 0.04001vs3
SD 838.50 30.91 378.98 579.24
Glucose at 0 OGTT (mmol/l) M 4,72 4.86 4.96 5.36 0.00131vs3
SD 0.73 0.65 0.70 0.86 <0.00011vs4
<0.00012vs4
<0.00013vs4
Glucose at 2-h OGTT (mmol/l) M 8.77 8.69 8.72 8.78 0.7755
SD 0.96 1.01 1.12 1.34
Minimal mean daily dose of insulin (U per day) M 9.75 14.29 15.08 19.09 0.00171vs4
SD 9.43 16.14 15.79 20.80
Maximal mean daily dose of insulin (U per day) M 19.93 41.02 49.10 59.41 0.04561vs2
SD 13.98 35.21 37.42 47.51 0.00111vs3
<0.00011vs4
Diet + insulin therapy N 43 71 79 126 <0.0001*
% 13,96 22,26 25,00 40,51
Data are presented as means + −SD for continuous traits or count (percentage) for categorical data.
p values are based on ANOVA test with post-hoc analysis.
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Table 3 Rating logistic regression model parameters for the dependent variable- therapy (diet vs diet + insulin) and
independent variables: age, pre-pregnancy BMI, fasting glucose, family history of diabetes, HOMA-IR and weight
accretion during pregnancy
Variables Chi2 β ORs 95% Cl p-Value
Age p < 0.0001 0.4302 1.54 (1.12–2.11) 0.008
BMI 0.3702 1.45 (1.03–2.03) 0.033
Glucose 0.9601 2.61 (1.48–4.50) 0.001
Family history of diabetes 0.2078 1.52 (0.82–2.81) 0.187
HOMA-IR 0.4047 3.37 (2.10–5.40) <0.0001
Weight gain at diagnosis of GDM −0.3287 0.72 (0.52–0.99) 0.042
BMI-body mass index, HOMA-IR - insulin resistance index.
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insulin resistance – as low as >1.29. The obtained results
stress the need for implementing a treatment aimed at
improving tissue susceptibility to insulin in GDM women
with a HOMA-IR of >1.29. It is especially important to
introduce healthy lifestyle changes, as well as a proper diet
based on individualized caloric needs and weight gain
[22]. It should be pointed out, that limiting excessive
growth of fatty tissue may also decrease the adverse effect
of adipokines on the insulin secretion [23] and reduce the
intensity of insulin resistance of skeletal muscles [6].
Since metformin reduces insulin resistance, metformin
treatment seems to be pathophysiologically sound in
most of the GDM women, with the exception of subjects
with a suspected of developing type 1 diabetes or with
type 1 diabetes exhibiting itself in the course of pregnancy.
Women with HOMA-IR values in the range of 1.92-2.89
exhibit a decreased beta cell function, suggesting insu-
lin substitution, rather than the introduction of oral
hypoglycemic drugs.
It is possible, based on existing evidence that starting
insulin substitution in the latter subpopulation of women
may delay the development of subsequent disturbances in
carbohydrate metabolism [24-26] and thus may partly
reduce future cardiovascular risk related to diabetes.
Women with HOMA-IR values of >2.89 are likely to
benefit from metformin treatment combined with insulin
therapy.
Another interesting finding in this study is the associ-
ation between the degree of insulin resistance, beta cell
function and the severity of GDM. Severity of GDM eval-
uated by starting insulin therapy and daily insulin dose,
exhibits the strongest correlation with HOMA-IR index
values. An increase in the HOMA index value of >2.89 is
accompanied both by an increase in insulin secretion and
by an increase in insulin requirement, which suggests
inefficient secretion in response to insulin resistance.
Our findings are in discordance with several up to day
published data performed in the small populations of
Caucasian GDM women [13,16,17] as well as in Japanese
women [27]. In these studies minimal increase in insulinsecretion assessed by HOMA B in the range of 80–130
to 170–180 [13,16] or by OGTT- derived indices of beta
cell function [27] fail to compensate for increased insulin
resistance assessed by HOMA-IR index between 1–1.8
to 2,3 contributed to the development of gestational
diabetes. In contrast, we show that basal insulin secretion
decrease in the range of HOMA-IR between 1 to 2,39. On
the other hand, these results my support our current
suggestion that there is a major need for a treatment
aimed at improving tissue insulin sensitivity at low insulin
resistance index-HOMA-IR values. In another observations,
beta-cell activity assessed by median of HOMA-B was equal
154 at the diagnosis of GDM [13] and 200 [17] alongside
with the HOMA-IR- 2.1 and 2.4 respectively.
Interestingly, most of these estimates of beta cell activity
are lower than those reported in our current study. We
suggest that the relatively early week of gestation at the
time of diagnosis of GDM as well as a younger age of
studied subjects in our data compared with most of other
studies [7,13,16,17,28] are partly responsible for these
differences. These discrepancies may be due to the small
size of populations studied as well as may reflect the
differences in diagnostic procedures, severity of glucose
intolerance, or anthropometric and ethnical [16] charac-
teristics. In the another study of large size population of
GDM women basal insulin secretion assessed by mean of
HOMA-B in whole population was equal 200 + −300
while the insulin sensitivity index derived from-OGTT
was reduced by 42% versus than in women with normal
glucose regulation [28]. These results are in accordance
with basal insulin secretory capacity values derived from
our current study and suggest pathophysiologic hetero-
geneity of the studied population of GDM women with
respect to this pathophysiological parameter. It is suggested
that results from HOMA-B a measure of basal insulin
secretory capacity should be interpreted alongside with
insulin sensitivity measure by HOMA-IR [29].
In general, our observations seem to be in line with data
which investigated insulin resistance during pregnancy
and its association with insulin therapy and beta cell
dysfunction during pregnancy [30-32].
Table 5 Logistic regression models of the dependent
variable maximal mean daily doses of insulin during
gestation, giving the individual odds ratio (OR) and its
confidence interval (CI) for statistically significant
parameters
Variable Chi2 β ORs 95% Cl p-Values
Model 1 0.0009
Age −0.1330 0.9 0.4–2.2 0.7699
BMI 0.1357 1.1 0.4–2.9 0.7764
HOMA-IR 0.6324 1.9 1.2–3.0 0.0105
Family history of diabetes 0.6093 1.8 0.8–4.2 0.1480
Glucose 0 1.0436 2.8 0.6–12.4 0.1644
Model 2 0.0019
Age −0.1166 0.9 0.4–2.2 0.7984
BMI 0.1674 1.2 0.5–3.1 0.7299
HOMA-IR 0.6286 1.9 1.2–3.0 0.0110
Family history of diabetes 0.6371 1.9 0.8–4.4 0.1347
Glucose 0 Weight accretion (kg) 1.0265 2.8 0.6–12.2 0.1711
0.1881 1.2 0.5–3.0 0.6794
Model 3 0.0008
Age −0.3630 0.7 0.3–1.8 0.4546
BMI 0.0454 1.0 0.4–2.8 0.9276
HOMA-IR 0.7091 2.0 1.2–3.4 0.0070
Family history of diabetes 0.6468 1.9 0.8–4.5 0.1374
Glucose 0 0.5349 1.7 0.4–8.2 0.5007
Glucose 2 h 1.0370 2.8 1.0–7.8 0.0447
HOMA-IR- insulin resistance index.
Table 4 Logistic regression models of the dependent
variable minimal mean daily dose of insulin at the
beginning of therapy, giving the individual odds ratios
(OR) and its confidence interval (CI) for statistically
significant parameters
Variable Chi2(p) β ORs 95% Cl p-Values
Model 1 0.0339
Age 0.1245 1.1 0.6–2.1 0.6923
BMI −0.0024 1.0 0.3–3.2 0.9968
HOMA-IR 0.4021 1.5 1.1–2.2 0.0500
Model 2 0.0155
Age 0.1347 1.1 0.6–2.1 0.6655
BMI −0.0643 0.9 0.5–1.9 0.8579
HOMA-IR 0.4474 1.6 1.1–2.2 0.0100
Gestational age (week) 0.5278 1.7 0.9–3.3 0.1129
Model 3 0.0393
Age 0.1366 1.1 0.6–2.1 0.6671
BMI −0.0624 0.9 0.5–1.9 0.8622
HOMA-IR 0.4452 1.6 1.1–2.2 0.0105
Gestational age (week) 0.4804 1.6 0.8–3.1 0.1515
Weight accretion (kg) 0.0098 1.0 0.5–1.9 0.9750
Model 4 0.0088
Age 0.0831 1.1 0.6–2.0 0.7975
BMI −0.0400 1.0 0.5–2.0 0.9150
HOMA-IR 0.3595 1.4 1.0–2.0 0.0425
Family history of diabetes 0.6474 1.9 1.1–3.3 0.0218
Model 5 < 0.0001
Age −0.4710 0.6 0.3–1.3 0.2269
HOMA-IR 0.1989 1.2 0.8–1.8 0.2938
Family 0.1864 1.2 0.6–2.5 0.6115
history of diabetes
Glucose 0 2.9081 18.3 4.7–70.9 <0.0001
Model 6 < 0.0001
Age −0.5454 0.6 0.3–1.2 0.1627
HOMA-IR 0.4368 1.5 1.1–2.2 0.0180
Family history of diabetes 0.3744 1.4 0.7–2.8 0.2635
Glucose 2 h 1.4621 4.3 2.0–9.3 0.0002
HOMA-IR- insulin resistance index.
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studies that insulin use during pregnancy is both a
parameter of GDM severity and a strong predictor for
the development of type 2 diabetes [31-33]. Our present
results suggest that the degree of insulin resistance, as
assessed by the HOMA-IR index at the diagnosis of
GDM, could be a potential predictor of GDM severity
and of the future development of type 2 diabetes, because
this parameter is associated with both beta cell dysfunc-
tion and insulin therapy.The importance of insulin resistance for beta cell
function in post-GDM has been partly illustrated by the
results of the Troglitazone In Prevention Of Diabetes
and Pioglitazone in Prevention of Diabetes studies, in
which the protection of beta cell function was closely
related to the degree of reduction in endogenous insulin
requirements [34].
We acknowledge, that estimation of insulin sensitivity
using HOMA-index is less precise than measurement
with an insulin clamp, but we consider that HOMA
method is more feasible in a large size cohort. Further,
we have established, that HOMA would be an accurate
measure of total insulin sensitivity thoroughout pregnancy
in women with gestational diabetes [35]. Additionally, re-
sults of some studies rise the pathophysiologic significance
of rather chronic hepatic insulin resistance [36] than the
whole-body insulin resistance in declining of beta cell
function in GDM women during pregnancy as well as
postpartum [37].
A limitation of our study is the use the fasting state
HOMA of beta cell function in population of GDM
women. There are no evidences that insulin secretion as
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http://www.biomedcentral.com/1472-6823/13/21assessed by HOMA-B index a surrogate of basal insulin se-
cretion is an adequate or is not adequate measure of beta
cell function in GDM women. Taken into consideration
the results of last data which suggest the pathophysiologic
importance of hepatic insulin resistance in GDM women,
the evaluation of basal insulin secretion may be a valuable
metabolic parameter in these group of women [36-38].
Certain limitation is the lack of information on the
dietary habits and the lifestyle prior to the study. Last
data revealed, that dietary factors, both before and during
pregnancy as well as physical activity are associated with
GDM risk [7].
Conclusions
We conclude that the degree of insulin resistance at the
diagnosis of GDM is a marker of GDM severity and
pathophysiological heterogeneity.
HOMA-IR values of ≥1.29 at diagnosis may indicate
insulin resistance to be the key pathophysiologic mech-
anism in GDM in the studied population of women.
These HOMA-IR values justify aggressive treatment of
insulin resistance as a method adequate to the patho-
physiologic background of GDM in this population of
Caucasian women. Decreased beta-cell function in
HOMA-IR values between 1.92-2.89 is associated with
decreased insulin secretion. Introduction of insulin
treatment in combination with dietary control seems to
be more appropriate in treating this subpopulation of
women than the administration of oral drugs. HOMA-IR
value of >2.89 suggests an inefficient compensation, thus
indicating the need for metformin treatment combined
with insulin therapy.
Further studies are needed to resolve the problem of
optimal treatment strategies, which still remain controversial
in this specific, high risk group of women.
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